Endocrine Society GUIDELINES Bundle (free trial)

Pediatric Obesity

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140160

Contents of this Issue

Navigation

Page 5 of 27

Diagnosis 6 Prehypertension and hypertension 3–11 y: (standardized according to sex, age, and height percentile) • BP >90th percentile to <95th percentile = prehypertension • BP ≥95th percentile to <99th percentile + 5 mm Hg = stage 1 HTN • BP ≥99th percentile + 5 mm Hg = stage 2 HTN 12–17 y: (standardized according to sex, age, and height percentile) • BP of >90th percentile to <95th percentile or >120/80 = prehypertension • BP ≥95th percentile to <99th percentile + 5 mm Hg = stage 1 HTN • BP ≥99th percentile + 5 mm Hg = stage 2 HTN 18–21 y: • BP ≥120/80 to 139/89 mm Hg = prehypertension • BP ≥140/90 to 159/99 mm Hg = stage 1 HTN • BP ≥160/100 to 179/109 mm Hg = stage 2 HTN • BP >180/110 mm Hg = stage 3 HTN NAFLD • ALT >25 U/L (boys) and >22 U/L (girls) PCOS • Free and total testosterone and SHBG, per Endocrine Society PCOS guidelines c Obstructive sleep apnea • If positive history, refer to pulmonary for nocturnal polysomnography and, if not available, overnight oximetry Psychiatric • If positive history, refer to mental health specialist a e test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay. b In the absence of unequivocal hyperglycemia, should be confirmed by repeat testing. c Given variability in testosterone levels and the poor standardization of assays, it is difficult to define an absolute level that is diagnostic of PCOS or other causes of hyperandrogenism (familiarity with local assays recommended). e preferred assay is HPLC tandem mass spectroscopy. Derived from (a) American Diabetes Association. Diabetes Care 2014;37(Suppl 1):S14–S80; (b) Expert Panel. Pediatrics 2011;128(Suppl 5): S213–S256; (c) Schwimmer JB et al. Gastroenterolog y 2010;138:1357–1364. e1–2; (d) Legro RS et al. J Clin Endocrinol Metab. 2013;98:4565–4592; (e) Wise MS et al. Sleep 2011;34:389–398; (f )Zametkin AJ. J Am Acad Child Adolesc Psychiatry 2004;43:134–150. Table 2. Screening for Comorbidities of Pediatric Overweight or Obesity (cont'd) Comorbidity Tests and Interpretation (To convert mg/dL to mmol/L, multiply by 0.0555 for glucose, 0.0259 for cholesterol, and 0.0113 for triglycerides.)

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Pediatric Obesity